1. First description of novel compound heterozygous mutations in HYCC1: clinical evaluations and molecular analysis in patient with hypomyelinating leukodystrophy-5 with retrospective view.
- Author
-
Ben Issa A, Kamoun F, Khabou B, Bouchaala W, Fakhfakh F, and Triki C
- Subjects
- Humans, Female, Young Adult, Hereditary Central Nervous System Demyelinating Diseases genetics, Hereditary Central Nervous System Demyelinating Diseases pathology, Genetic Association Studies methods, Phenotype, Retrospective Studies, Models, Molecular, Pedigree, Heterozygote, Mutation
- Abstract
Hypomyelinating leukodystrophy-5 (HLD5) is a rare autosomal recessive hypomyelination disorder characterized by congenital cataract, progressive neurologic impairment, and myelin deficiency in the central and peripheral nervous system, caused by mutations in the HYCC1 gene. Here we report a 23-year-old girl with HLD5 from unrelated families. Molecular analysis was performed using sequence screening of the HYCC1 gene. In addition, in silico prediction tools and molecular investigation were used to predict the structural effect of the mutations. Results showed a novel compound heterozygous mutation in the HYCC1 gene. Moreover, in silico tools and 3D structural modeling revealed that c.521C > A (p.Ala174Glu) and c.652C > G (p.Gln218Glu) mutations could affect the structure, stability, and conformational analyses in the N-ter domain of the Hyccin protein. We also, we compared the phenotype of our patient with those of previously reported cases with HLD5 syndrome and our findings indicate the absence of reliable genotype-phenotype correlations. To the best of our knowledge, this is the first report describing a Tunisian HLD5 patient with compound heterozygous mutations (c.521C > A (p.Ala174Glu) and c.652C > G (p.Gln218Glu)) in HYCC1 gene., Competing Interests: Competing interests: The authors declare no competing interests. Ethical approval: The study was conducted in accordance with the principles stated in the Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects, Helsinki, Finland, 1964, and as amended in Fortaleza, Brazil, 2013. The study design was approved by the committee on research ethics of the University of Sfax, Tunisia. Consent to participate: Informed consent for publication of this study was obtained from all patients and/or families involved. Consent for publication: We certify that all contributors have read and approved the submission to this journal and that there is no financial or commercial involvement, or other conflict of interest by any author., (© 2024. The Author(s), under exclusive licence to The Japan Society of Human Genetics.)
- Published
- 2025
- Full Text
- View/download PDF